methylprednisolone and Immunoblastic Large-Cell Lymphoma

methylprednisolone has been researched along with Immunoblastic Large-Cell Lymphoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bastion, Y; Baumelou, E; Bouabdallah, K; Delannoy, A; Dupriez, B; Haioun, C; Herbrecht, R; Morel, P; Nouvel, C; Tilly, H1
Amiot, L; Caulet-Maugendre, S; Diebold, J; Drénou, B; Fardel, O; Fauchet, R; Lamy, T; Le Prisé, PY; Sasportes, M1

Trials

1 trial(s) available for methylprednisolone and Immunoblastic Large-Cell Lymphoma

ArticleYear
Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
    British journal of cancer, 1994, Volume: 70, Issue:1

    Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distribution; Creatinine; Cyclophosphamide; Doxorubicin; Female; Humans; Kidney; Kidney Neoplasms; L-Lactate Dehydrogenase; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Neoplasm Staging; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Vindesine

1994

Other Studies

1 other study(ies) available for methylprednisolone and Immunoblastic Large-Cell Lymphoma

ArticleYear
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
    Blood, 1997, Apr-15, Volume: 89, Issue:8

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; CD3 Complex; CD56 Antigen; Cell Nucleus; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Herpesvirus 4, Human; Humans; Idarubicin; Immunophenotyping; Killer Cells, Natural; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Pelvic Neoplasms; Prednisone; Quinine; Vincristine

1997